Charles River Laboratories Rating Reiterated by Deutsche Bank (CRL)
Charles River Laboratories (NYSE:CRL)‘s stock had its “hold” rating reiterated by investment analysts at Deutsche Bank in a note issued to investors on Wednesday. They currently have a $59.00 price target on the stock, up from their previous price target of $58.00. Deutsche Bank’s price objective would suggest a potential upside of 0.48% from the company’s current price.
In other Charles River Laboratories news, Director Richard F. Wallman unloaded 3,240 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $58.20, for a total value of $188,568.00. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Other equities research analysts have also recently issued reports about the stock. Analysts at Credit Suisse reiterated a “neutral” rating on shares of Charles River Laboratories in a research note on Friday, August 8th. They now have a $60.00 price target on the stock, up previously from $56.00. Separately, analysts at SunTrust initiated coverage on shares of Charles River Laboratories in a research note on Tuesday, June 24th. They set a “neutral” rating and a $55.00 price target on the stock. Finally, analysts at Morgan Stanley reiterated an “equal weight” rating on shares of Charles River Laboratories in a research note on Tuesday, May 20th. They now have a $60.00 price target on the stock. Eight investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $58.00.
Charles River Laboratories (NYSE:CRL) traded down 0.20% during mid-day trading on Wednesday, hitting $58.60. 859,902 shares of the company’s stock traded hands. Charles River Laboratories has a 1-year low of $44.12 and a 1-year high of $62.50. The stock has a 50-day moving average of $53.98 and a 200-day moving average of $55.9. The company has a market cap of $2.735 billion and a P/E ratio of 24.02.
Charles River Laboratories (NYSE:CRL) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.82 by $0.15. The company had revenue of $341.18 million for the quarter, compared to the consensus estimate of $327.96 million. During the same quarter last year, the company posted $0.73 earnings per share. Charles River Laboratories’s revenue was up 16.5% compared to the same quarter last year. On average, analysts predict that Charles River Laboratories will post $3.32 earnings per share for the current fiscal year.
Charles River Laboratories International, Inc is a global provider of solutions, which accelerate the early-stage drug discovery and development process.
Receive News & Ratings for Charles River Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.